IPG Investment Advisors LLC acquired a new position in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,212 shares of the financial services provider’s stock, valued at approximately $236,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Parametric Portfolio Associates LLC boosted its stake in iShares NASDAQ Biotechnology Index by 8.7% during the second quarter. Parametric Portfolio Associates LLC now owns 988 shares of the financial services provider’s stock worth $306,000 after buying an additional 79 shares during the period. Bank Hapoalim BM lifted its position in shares of iShares NASDAQ Biotechnology Index by 2.5% during the third quarter. Bank Hapoalim BM now owns 6,819 shares of the financial services provider’s stock worth $2,275,000 after purchasing an additional 169 shares during the last quarter. Adell Harriman & Carpenter Inc. lifted its position in shares of iShares NASDAQ Biotechnology Index by 1.3% during the third quarter. Adell Harriman & Carpenter Inc. now owns 14,738 shares of the financial services provider’s stock worth $4,916,000 after purchasing an additional 190 shares during the last quarter. Parsec Financial Management Inc. lifted its position in shares of iShares NASDAQ Biotechnology Index by 1.0% during the third quarter. Parsec Financial Management Inc. now owns 19,566 shares of the financial services provider’s stock worth $6,527,000 after purchasing an additional 194 shares during the last quarter. Finally, Orleans Capital Management Corp LA lifted its position in shares of iShares NASDAQ Biotechnology Index by 13.4% during the third quarter. Orleans Capital Management Corp LA now owns 1,695 shares of the financial services provider’s stock worth $565,000 after purchasing an additional 200 shares during the last quarter. 27.28% of the stock is owned by institutional investors.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ IBB) opened at $107.35 on Tuesday. iShares NASDAQ Biotechnology Index has a 52-week low of $94.20 and a 52-week high of $119.30.

TRADEMARK VIOLATION NOTICE: “IPG Investment Advisors LLC Acquires Shares of 2,212 iShares NASDAQ Biotechnology Index (IBB)” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://theolympiareport.com/2018/02/13/ipg-investment-advisors-llc-acquires-shares-of-2212-ishares-nasdaq-biotechnology-index-ibb.html.

iShares NASDAQ Biotechnology Index Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.